> Details

Hart, Daniel P.; Alamelu, Jayanthi; Bhatnagar, Neha; Biss, Tina; Collins, Peter W.; Hall, Georgina; Hay, Charles; Liesner, Ri; Makris, Michael; Mathias, Mary; Motwani, Jayashree; Palmer, Ben; Payne, Jeanette; Percy, Charles; Richards, Michael; Riddell, Anne; Talks, Kate; Tunstall, Oliver; Chalmers, Elizabeth

Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update
  • Contributor: Hart, Daniel P.; Alamelu, Jayanthi; Bhatnagar, Neha; Biss, Tina; Collins, Peter W.; Hall, Georgina; Hay, Charles; Liesner, Ri; Makris, Michael; Mathias, Mary; Motwani, Jayashree; Palmer, Ben; Payne, Jeanette; Percy, Charles; Richards, Michael; Riddell, Anne; Talks, Kate; Tunstall, Oliver; Chalmers, Elizabeth
  • Published: Wiley, 2021
  • Published in: Haemophilia, 27 (2021) 6, Seite 932-937
  • Language: English
  • DOI: 10.1111/hae.14381
  • ISSN: 1351-8216; 1365-2516
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>In good risk patients (historic inhibitor peak &lt; 200BU), the International Immune Tolerance Study demonstrated equal efficacy to induce tolerance between high (200iu/kg/day) and low dose (50iu/kg ×3 times/week) immune tolerance induction (ITI) regimens. However, the trial stopped early on account of the excessive bleed rate in the low dose ITI arm.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>United Kingdom Haemophilia Centre Doctors’ Organization (UKHCDO) Paediatric and Inhibitor working parties considered available ITI data alongside the bi‐phenotypic antibody emicizumab (Hemlibra®) efficacy and safety data to develop a consensus guideline for the future UK ITI guideline.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This revision of UKHCDO ITI guidance incorporates the recommendation to use emicizumab as a prophylaxis haemostatic agent to reduce bleeding rates and to facilitate low dose and reduced frequency of FVIII CFC for ITI in the majority of children.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This consensus protocol will facilitate future evaluation of ITI outcomes in the evolving landscape of haemophilia therapeutics and ITI strategies.</jats:p></jats:sec>